NCT02718118已完成4 期
A Prospective, Randomized, Multi-Center, Subject- and Evaluator-Blinded, Parallel Comparison of Dysport®, When Reconstituted at 1.5 mL and 2.5 mL, for the Treatment of Moderate to Severe Glabellar Lines.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Galderma R&D
- 入组人数
- 60
- 试验地点
- 3
- 主要终点
- Proportion of Composite Responders Who Achieve at Least a 1-point Reduction From Baseline in Glabellar Line Severity Score (GLSS) at Maximum Frown.
研究概览
简要总结
This study is designed to evaluate the safety, efficacy, and subject and investigator satisfaction of 2 different injection volumes of Dysport in the glabellar lines.
- To determine the proportion of composite responders (based on blinded evaluator and subject assessments) who achieve at least a 1-point reduction from baseline in glabellar line severity score (GLSS) at maximum frown line on Day 30.
- To assess the GLSS, at maximum frown and at rest, by live assessment at all visits.
- To evaluate the onset of effect on appearance of glabellar lines starting at the Day 2 visit (subject and blinded evaluator).
- To assess the subject's satisfaction with the treatment.
- To evaluate investigator satisfaction of treatment outcome.
- To evaluate subject psychological well-being.
- To evaluate subject age appraisal.
- To evaluate all adverse events during the course of the study.
详细描述
Five month, randomized, subject- and evaluator-blinded, multi-center, mult-visit study. Subjects treated with Dysport following the US on-label guidelines.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Botulinum toxin naïve subject (facial area)
- •Moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown and mild to severe (GLSS = 1, 2, or 3) glabellar lines at rest using the validated 4-point Photographic Scale, as assessed by the treating investigator and the blinded evaluator.
排除标准
- •Have known allergies or sensitivities to Dysport®, any of its excipients, or cow's milk protein
- •Have rhytids of the glabellar region that cannot be smoothed out by manually spreading the skin apart
- •Have a history or have signs and symptoms of eyelid or brow ptosis or signs of compensatory frontalis muscle activity, as judged by the investigator
- •Have clinical or subclinical neuromuscular junctional disorders (eg, myasthenia gravis, Lambert Eaton syndrome, or amyotrophic lateral sclerosis) or a history of dysphagia or aspiration
- •Are women who are pregnant or breast-feeding or who intend to get pregnant within the duration of the study
- •Have an active inflammation or infection in the areas to be treated or had any prior surgery, tattoos, piercings, or scarring in the facial area that, in the opinion of the investigator, may interfere with the results
- •Have had any previous insertion of any permanent or semi-permanent material, hyaluronic acid, or collagen fillers in the glabellar region
- •Have any chronic or acute medical condition that, may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this study
结局指标
主要结局
Proportion of Composite Responders Who Achieve at Least a 1-point Reduction From Baseline in Glabellar Line Severity Score (GLSS) at Maximum Frown.
时间窗: 30 days
Proportion of composite responders who achieve at least a 1-point reduction from baseline in glabellar line severity score (GLSS) based on subject and blinded-evaluator assessment of glabellar line severity at maximum frown on Day 30.
次要结局
- Proportion of Combination Responders, at Maximum Frown (Blinded Evaluator and Subject)(120 days)
- Subject Age Appraisal Using the FACE-Q-Age Appraisal Visual Analog Scale (VAS) - Mean Change at Day 120 Compared to Baseline(Baseline and Day 120)
- Investigator Satisfaction With Treatment Outcome - Satisfied With the Study Product Results(30 days)
- Subject Psychological Well-being - Mean Change at Day 120 Compared to Baseline(Baseline and Day 120)
- Proportion of Responders, at Maximum Frown (Blinded Evaluator)(120 days)
- Proportion of Responders, at Maximum Frown (Subject)(120 days)
- Proportion of Combination Responders, at Rest (Blinded Evaluator and Subject)(120 days)
- Proportion of Responders, at Maximum Frown (Treating Investigator)(120 days)
- Proportion of Responders, at Rest (Blinded Evaluator)(120 days)
- Proportion of Responders, at Rest (Subject)(120 days)
- Proportion of Responders, at Rest (Treating Investigator)(120 days)
- Proportion of Subjects Who Achieved an Onset of Effect on the Appearance of the Subject's Glabellar Lines.(7 days)
- Subject Appraisal of Lines Between the Eyebrows (FACE-Q) - Mean Change at Day 120 Compared to Baseline(Baseline and Day 120)
- Subject Satisfaction With the Treatment of Glabellar Lines - I am Satisfied With How I Look.(120 days)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
不适用
RHEIA (Randomized researcH in womEn All Comers With Aortic Stenosis)Aortic Valve StenosisHeart Valve DiseasesNCT04160130Optimapharm432
Unknown
不适用
Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV FistulaArteriovenous FistulaNCT04393688BrosMed Medical Co., Ltd168
撤回
不适用
Efficacy of the Aspen Spinous Process System in Anterior Lumbar Interbody Fusion (ALIF)Degenerative Disc DiseaseNCT01016314Zimmer Biomet
招募中
不适用
Efficacy and Safety of Sirolimus-Coated Spiral Balloon for Coronary Bifurcation LesionsCoronary Bifurcation LesionNCT06618248Dongguan TT Medical280
招募中
不适用
Coronary Non-slip Balloon Catheter in Patients With Coronary Artery Stenosis(CREST)Coronary Artery StenosisNCT05606367Shanghai MicroPort Rhythm MedTech Co., Ltd.200